Getting a new treatment to market depends on more than clinical results. It depends on demonstrating value to the people who decide on patient access, from payers and regulators to clinicians and the patients themselves.

That is what Cogentia works on every day. We believe evidence and access should be considered together from the earliest stages of development, so that each shapes the other as a product moves toward market.

We are an established and growing health economics and market access consultancy based in Cambridge, UK, supporting pharmaceutical, biotech and medtech companies worldwide since 2010. Our team of health economists, market access specialists and strategists works across disciplines, from early landscape assessment and payer research through to global value dossiers, health technology assessment submissions and access negotiations.

We are part of the Helios Global Group, a leader in global healthcare communications.